Soru

Zorluk: ZorGastroenterology and Hepatology

A 5858-year-old man is evaluated in the hospital on day 44 of admission for a pyogenic liver abscess. He initially presented with a 11-week history of right upper quadrant pain, high-grade fever, and chills. On admission, computed tomography of the abdomen revealed a 5.55.5-cm fluid collection in the right hepatic lobe. He underwent prompt percutaneous catheter drainage and was empirically started on intravenous piperacillin-tazobactam.

Over the past 4848 hours, his clinical condition has markedly improved. He is currently tolerating a regular diet and has been afebrile for two days. Current vital signs are:
Temperature: 37.1∘C37.1^\circ C (98.8∘F98.8^\circ F)
Blood pressure: 128/78128/78 mmHg
Pulse: 76/min76/min
Respirations: 14/min14/min

Laboratory results today show a leukocyte count of 8,500/μL8,500/\mu L, down from 18,200/μL18,200/\mu L on admission. The percutaneous drain is currently putting out 1010 mL of serosanguinous fluid daily.

The abscess fluid culture from day 11 has finalized and is growing *Streptococcus anginosus*. Susceptibility testing results are as follows:

Antimicrobial AgentSusceptibility
AmpicillinSusceptible
CeftriaxoneSusceptible
CiprofloxacinResistant
Piperacillin-tazobactamSusceptible
VancomycinSusceptible

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Transition to oral amoxicillinCevap
  2. B
    Continue intravenous piperacillin-tazobactam
  3. C
    Transition to oral ciprofloxacin and metronidazole
  4. D
    Add intravenous vancomycin
  5. E
    Discontinue all antimicrobial therapy

Cevap

The most appropriate next step is to transition the patient to oral amoxicillin.
This patient has a pyogenic liver abscess that has been successfully managed with percutaneous catheter drainage (source control) and initial empiric intravenous antibiotics. He is now clinically stable, afebrile for 4848 hours, and tolerating a regular diet. These milestones fulfill the clinical criteria for transitioning from intravenous to oral antimicrobial therapy. The abscess fluid culture has identified a monomicrobial infection with *Streptococcus anginosus*, which susceptibility testing confirms is sensitive to ampicillin. Oral amoxicillin provides excellent oral bioavailability, effectively targets the isolated organism, and represents the ideal narrow-spectrum agent. Transitioning to oral amoxicillin aligns directly with core antibiotic stewardship principles by de-escalating therapy to the narrowest effective spectrum, allowing for safe hospital discharge while completing the required 44 to 66 week total antibiotic course.

Adım Adım Çözüm

1
Assess the patient's clinical trajectory and criteria for step-down therapy.
The patient is afebrile, tolerating an oral diet, and has a normalized leukocyte count, indicating clinical stability and adequate source control.
Clinical stability dictates the safe timing for transition from intravenous to oral antimicrobial therapy.
2
Analyze the culture and susceptibility data.
The abscess fluid grew *Streptococcus anginosus*, which is susceptible to ampicillin but resistant to ciprofloxacin.
Definitive therapy must be tailored to the specific causative organism and its unique susceptibility profile.
3
Apply principles of antibiotic stewardship to modify the pharmacotherapy.
De-escalate from the broad-spectrum empiric regimen (piperacillin-tazobactam) to a targeted, highly bioavailable narrow-spectrum oral agent (amoxicillin).
Narrow-spectrum targeted therapy effectively eradicates the infection while minimizing the risk of multi-drug resistance and collateral damage to the host microbiome.

Anahtar Kavram

In a clinically stable patient with a drained pyogenic liver abscess, broad-spectrum intravenous antibiotics should be de-escalated to targeted, narrow-spectrum oral therapy based on specific culture and susceptibility data.
Bu soruyu puanla